Cargando…
721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
BACKGROUND: Multidrug-resistant Gram-negative bacteria have become a serious problem in hospitals worldwide. Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a wide range of carbapenemase- and ESBL-producing bacteria. We tested the activity of CFDC against (1) a recent c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811323/ http://dx.doi.org/10.1093/ofid/ofz360.789 |
_version_ | 1783462456716165120 |
---|---|
author | Iregui, Alejandro Khan, Zeb Landman, David Quale, John M |
author_facet | Iregui, Alejandro Khan, Zeb Landman, David Quale, John M |
author_sort | Iregui, Alejandro |
collection | PubMed |
description | BACKGROUND: Multidrug-resistant Gram-negative bacteria have become a serious problem in hospitals worldwide. Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a wide range of carbapenemase- and ESBL-producing bacteria. We tested the activity of CFDC against (1) a recent collection of clinical isolates and (2) a separate collection of carbapenem-resistant isolates gathered from NYC hospitals. METHODS: Susceptibility testing was performed on isolates of E. coli, K. pneumoniae, Enterobacter spp., P. aeruginosa, and A. baumannii gathered in 2017 from 7 hospitals in Brooklyn, NY. Consecutive unique patient clinical isolates from all sources were collected for a three month period. Testing was also done on a collection of carbapenem-resistant isolates from a similar surveillance study conducted in 2013–2014. MICs were performed with iron-depleted cation-adjusted Mueller–Hinton broth for CFDC and agar dilution for other antibiotics according to CLSI methodology. The provisional CLSI breakpoint (≤4 μg/mL susceptible) was used for CFDC. Cephalosporin-resistant isolates were tested for common carbapenemases by PCR. RESULTS: The susceptibility results for CFDC and meropenem for the isolates gathered in 2017 are listed in the Table. All of the Enterobacteriacae were susceptible to CFDC including KPC-possessing E. coli (n = 4), K. pneumoniae (n = 20), and Enterobacter spp (n = 3). 99.6% of P. aeruginosa and 100% of A. baumannii (including 8 with bla(OXA-23), 2 with bla(OXA-24), and 1 with bla(KPC)) were susceptible to CFDC. For the collection of carbapenem-resistant isolates gathered in 2013–14, 100% of K. pneumoniae (n = 111), 100% of P. aeruginosa (n = 130), and 90% of A. baumannii (n = 78) were susceptible to CFDC. CONCLUSION: CFDC has excellent in vitro activity against Gram-negative clinical isolates from NYC, including a large collection of carbapenem-resistant Enterobacteriaceae, P. aeruginosa, and A. baumannii. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6811323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68113232019-10-29 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City Iregui, Alejandro Khan, Zeb Landman, David Quale, John M Open Forum Infect Dis Abstracts BACKGROUND: Multidrug-resistant Gram-negative bacteria have become a serious problem in hospitals worldwide. Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a wide range of carbapenemase- and ESBL-producing bacteria. We tested the activity of CFDC against (1) a recent collection of clinical isolates and (2) a separate collection of carbapenem-resistant isolates gathered from NYC hospitals. METHODS: Susceptibility testing was performed on isolates of E. coli, K. pneumoniae, Enterobacter spp., P. aeruginosa, and A. baumannii gathered in 2017 from 7 hospitals in Brooklyn, NY. Consecutive unique patient clinical isolates from all sources were collected for a three month period. Testing was also done on a collection of carbapenem-resistant isolates from a similar surveillance study conducted in 2013–2014. MICs were performed with iron-depleted cation-adjusted Mueller–Hinton broth for CFDC and agar dilution for other antibiotics according to CLSI methodology. The provisional CLSI breakpoint (≤4 μg/mL susceptible) was used for CFDC. Cephalosporin-resistant isolates were tested for common carbapenemases by PCR. RESULTS: The susceptibility results for CFDC and meropenem for the isolates gathered in 2017 are listed in the Table. All of the Enterobacteriacae were susceptible to CFDC including KPC-possessing E. coli (n = 4), K. pneumoniae (n = 20), and Enterobacter spp (n = 3). 99.6% of P. aeruginosa and 100% of A. baumannii (including 8 with bla(OXA-23), 2 with bla(OXA-24), and 1 with bla(KPC)) were susceptible to CFDC. For the collection of carbapenem-resistant isolates gathered in 2013–14, 100% of K. pneumoniae (n = 111), 100% of P. aeruginosa (n = 130), and 90% of A. baumannii (n = 78) were susceptible to CFDC. CONCLUSION: CFDC has excellent in vitro activity against Gram-negative clinical isolates from NYC, including a large collection of carbapenem-resistant Enterobacteriaceae, P. aeruginosa, and A. baumannii. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811323/ http://dx.doi.org/10.1093/ofid/ofz360.789 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Iregui, Alejandro Khan, Zeb Landman, David Quale, John M 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City |
title | 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City |
title_full | 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City |
title_fullStr | 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City |
title_full_unstemmed | 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City |
title_short | 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City |
title_sort | 721. in vitro activity of cefiderocol against gram-negative clinical isolates from new york city |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811323/ http://dx.doi.org/10.1093/ofid/ofz360.789 |
work_keys_str_mv | AT ireguialejandro 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity AT khanzeb 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity AT landmandavid 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity AT qualejohnm 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity |